Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infec... (www.optimerpharma.com/ target

HOME >> MEDICINE >> TECHNOLOGY

Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)

Date:9/15/2009

www.optimerpharma.com/" target="_new">www.optimerpharma.com.

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the ability of fidaxomicin to treat CDI and address current treatment limitations. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its preclinical and clinical development of potential drugs and other risks detailed in Optimer's filings with the Securities and Exchange Commission.

    Contacts

    Optimer Pharmaceuticals, Inc.
    John Prunty, CFO & VP, Finance
    Christina Donaghy, Corporate Communications Manager
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results

Post Your Comments:

(Date:12/14/2009)... Associates, a leading public affairs agency providing ... issues management, today announced that it has ... PSID ) to serve as the ... Associates will conduct media relations for PositiveID,s ... its public relations programs. ,, PositiveID, headquartered ...

(Date:12/14/2009)... Pa., Dec. 14 At GeoInvesting.com, we have ... for some time now. Our largest hang up had ... the Company,s fiscal June 2010 net income guidance of ... 2009 reported net income of $7.9 million, the increase ... EPS growth scenario, which depends upon the share price ...

(Date:12/14/2009)... Dec. 14 When staff from a ... apply the difficult to adjust and uncomfortable cubital ... Professional Products, Inc. (PPI) to develop a superior ... orthopaedic solutions for nearly five decades, responded with ... ), which it announced today. Simple to ...

Breaking Medicine Technology:Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2 GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2 New Cubital Tunnel Splint Specially Designed for Comfort and Less Cumbersome Fit 2 New research shows dinosaurs may have been smaller than we thought 9003 1 New research shows dinosaurs may have been smaller than we thought 9003 2 Innovative Psoriasis Treatment PSORENT 28R 29 Announces Healthcare Cost Savings Potential Consistent with President Obamas Announcement on Healthcare 4651 1 Innovative Psoriasis Treatment PSORENT 28R 29 Announces Healthcare Cost Savings Potential Consistent with President Obamas Announcement on Healthcare 4651 2 Respiratory Rally a Promising Practice in the Fight Against Chronic Disease 50062 1 Respiratory Rally a Promising Practice in the Fight Against Chronic Disease 50062 2

[0] Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation [0] GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms [0] New Cubital Tunnel Splint Specially Designed for Comfort and Less Cumbersome Fit

... to Advance to Phase Three Trials FRAZER, Pa., March ... CEPH ) today announced positive results from a phase ... adjunctive therapy for treating major depressive disorder in adults ... American adults are affected by bipolar I disorder, which ...

... Today at 5:00 p.m. Eastern Time - SOUTH SAN ... PARD ), a biopharmaceutical company focused on ... and year ended December 31, 2008, and provided a ... made significant progress toward our goal of developing picoplatin ...

Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update

(Date:12/14/2009)... In today,s academic medical centers, value ... Now the University HealthSystem Consortium (UHC) has created ... Achieving Cost Efficiencies in Health Care, to ... These new materials, developed with the input of ... practical guide to planning, implementing, and managing all ...

(Date:12/14/2009)... Fla., Dec. 14 Abbott (NYSE: ... definitive agreement to acquire STARLIMS Technologies Ltd. ... of laboratory information management systems, for approximately ... acquisition strengthens Abbott,s competitive position in the ... to help laboratories efficiently store, retrieve and ...

(Date:12/14/2009)... Aflac Incorporated announced today that it has priced ... with a coupon of 6.9%. The notes will ... yield 6.984%. The company anticipates using the proceeds ... corporate purposes. ,, Commenting on the pricing of ... Financial Officer Kriss Cloninger III commented: "This debt ...

(Date:12/14/2009)... researchers say , , MONDAY, Dec. 14 (HealthDay News) -- ... a single gene linked to heart failure. , The ... Louis analyzed the DNA of a large group of ... in four genes that could be connected with heart ... and 625 healthy whites led the researchers to identify ...

(Date:12/14/2009)... procedures vary widely and are higher than generally thought, raising concerns ... by University of California, San Francisco (UCSF) imaging specialists. ... ... -- Radiation doses from common CT procedures vary widely and are ... according to a new study led by University of California, ...

Breaking Medicine News(10 mins):Health News:University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources 2 Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2 Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3 Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4 Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2 Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3 Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5

[1] University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources [0] Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems [0] Aflac Incorporated Prices $400 Million of 30-Year Senior Notes [0] Contributors to Heart Failure Identified [0] Variable Doses of Radiation Raise Safety Concerns for CT Procedures

... Kensey Nash Corporation,(Nasdaq: KNSY ) is scheduled ... at the Grand Hyatt New York Hotel in New ... Evans, Kensey Nash,s COO, will deliver the Company,s,presentation, beginning ... of the Kensey Nash presentation at the FBR conference, ...

... in Discovery Green Park, HOUSTON, May 23 ... year,s presidential election and the cost of health care,continuing ... (HJMHF) will offer Houston residents a fun and informative,opportunity ... The multicultural health event, which will kick off ...

... 32, was indicted by a grand jury in ... the operation of an,illegal Internet pharmacy, Assistant Attorney ... U.S. Attorney Patrick L. Meehan for the,Eastern District ... charged with four counts of distribution of controlled,substances ...

... risk, healthy eating and exercise can delay disease, researchers say ... programs for people at high risk for developing diabetes, when ... diabetes for 14 years after the programs end, a new ... 24 special diabetes issue of The Lancet . , ...

... cause of some forms of vision loss , ... protease inhibitors has been suggested by a team of researchers ... a result of their work in a mouse model of ... many diseases of the eye is the death (by a ...

... CRGN ) announced today the completion of ... Company sold the 5,000,000 shares of,TopoTarget common stock ... the,sale of CuraGen,s ownership in belinostat. After expenses, ... "We are pleased to announce the planned, orderly ...

Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference Announcing the 2nd Annual Houston Juneteenth Multicultural Health Festival California Man Indicted For Conspiracy In Operating Internet Pharmacy Lifestyle Changes Can Keep Diabetes at Bay for 14 Years JCI table of contents: May 22, 2008 CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Vancomycin, Trough Level Vancor, Random Level Vancocin, Trough Level Vancomycin, Random Level

Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infec...(www.optimerpharma.com/ target _new www...),Health